AAP
TELO icon

Arax Advisory Partners’s Telomir Pharmaceuticals TELO Stock Holding History

Arax Advisory Partners’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9
Closed -$12 – 4581
2025
Q3 		$12 Buy
+9
New +$14 ﹤0.01% 3589

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Arax Advisory Partners's TELO Position: Q4 2025 in Review

Arax Advisory Partners sold out of Telomir Pharmaceuticals (TELO) in Q4 2025, closing a stake of 9 shares — an estimated $12 sold.

Arax Advisory Partners first reported a position in TELO in Q3 2025 and held it in 1 quarter. The position peaked at $12 in Q3 2025. 33 funds tracked by Wall St. Rank hold TELO as of Q4 2025.

  • Arax Advisory Partners reported no remaining Telomir Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 9 Telomir Pharmaceuticals shares in Q4 2025, an estimated $12.
  • Arax Advisory Partners first reported a position in Telomir Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Telomir Pharmaceuticals position peaked at $12 in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.